New therapy target could prevent blindness in premature babies

17 September 2014

A new study has suggested a treatment that could prevent premature babies from losing their sight. The research, conducted at Sainte-Justine University Hospital Research Center (Sainte-Justine UHC) and Université de Montréal, focused on activating a receptor that moves to the nucleus in nerve cells.

This receptor then promotes the growth of blood vessels and could open up the possibility of developing new drug-based treatments for premature babies, who are at risk of losing their sight.

The findings, published in the medical journal Nature Medicine, could see more selective drugs being created that are able to manage the abnormal growth of blood vessels, which would prevent blindness including retinopathy of prematurity, a disorder that may result in retinal detachment due to abnormal blood vessel growth in the retina of the eye.

"This study shows that a single receptor may play various roles depending on whether its site of action is in the nucleus or on the cell membrane," said Dr Jean-Sébastien Joyal, a pediatric intensivist at the Sainte-Justine UHC and an assistant professor at the Université de Montréal. 

Posted by Philip Briggs​


Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)